View Future GrowthCell Source 과거 순이익 실적과거 기준 점검 0/6Cell Source의 연간 평균 수익은 0.7%였으며, Biotechs 산업의 수익은 연간 36.2% 증가했습니다.핵심 정보0.70%순이익 성장률10.75%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률n/a자기자본이익률n/a순이익률n/a최근 순이익 업데이트31 Mar 2025최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Mar 29Cell Source, Inc. announced delayed annual 10-K filingOn 03/28/2025, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Nov 21Cell Source, Inc. Shared Positive Interim Results from Its Phase 1/2 First-In-Human Clinical Trial Conducted At the University of Texas Md Anderson Cancer CenterCell Source, Inc. shared positive interim results from its Phase 1/2 First-in-Human clinical trial conducted at The University of Texas MD Anderson Cancer Center. The trial has treated 15 patients using Cell Source's proprietary Veto Cell technology in stem cell transplants for malignant and non-malignant hematologic diseases. These early results indicate both safety and efficacy, marking a promising advance in stem cell transplant outcomes. Breakthrough Results for Safer and Effective Transplants Previously presented at the American Society for Hematology (ASH) Annual Meeting, the interim study results highlight: Consistent engraftment without severe GvHD: Achieved at 42 days post- transplant with T-cell-depleted, haploidentical stem cell transplants under reduced intensity conditioning (RIC).No toxicity linked to Veto Cells: No patients experienced adverse effects directly associated with Veto Cells. Enhanced protocol: A mild conditioning regimen, combined with Rituximab to prevent antibody-related complications, makes transplants safer and suitable for a broader range of patients. These findings underscore the potential of Veto Cells to increase access to life-saving allogeneic transplants for cancer patients and individuals with non-malignant blood disorders, supporting the strategic advancement of Cell Source's technology. Comparable Successes Demonstrate Market Potential The cell therapy and immunotherapy market has seen robust investor interest, with several start-up companies achieving multibillion-dollar valuations after clinical success. For example, Kite Pharma and Juno Therapeutics were acquired for $12 billion and $9 billion, respectively, following successful clinical outcomes and regulatory approvals in similar areas of cellular therapy. These precedents highlight the significant financial upside for novel treatments that achieve distinctive clinical efficacy and regulatory milestones. With Cell Source's Veto Cell platform showing early promise in achieving safer and thus more effective stem cell transplants without severe GvHD, the Company is strategically positioned to capitalize on this expanding market. The total addressable market (TAM) for hematological therapeutics, including both cancer and nonmalignant diseases, is estimated to be in excess of $100 billion, underscoring the vast commercial potential for Veto Cells to gain market traction as the platform advances through clinical trials. Pathway to Market and Competitive EdgeCell Source's Veto Cell technology offers a unique advantage by combining reduced immune suppression with avoidance to GvHD, making it an attractive alternative to current stem cell transplant methods. The Company's Veto Cell platform is also being developed for organ transplant applications, potentially allowing for partially mismatched donors as well as reducing or possibly even eliminating reliance on lifelong immunosuppression post-transplant.공시 • Aug 15Cell Source, Inc. announced delayed 10-Q filingOn 08/14/2024, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 02Cell Source, Inc. announced delayed annual 10-K filingOn 04/01/2024, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Aug 17Cell Source, Inc. announced delayed 10-Q filingOn 08/15/2023, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.New Risk • Jun 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$2.9m free cash flow). Shares are highly illiquid. Negative equity (-US$12m). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$14.9k market cap). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Shareholders have been diluted in the past year (8.0% increase in shares outstanding).공시 • May 17Cell Source, Inc. announced delayed 10-Q filingOn 05/16/2023, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Jul 22Cell Source, Inc. Announces Board ResignationsCell Source, Inc. announced that onJuly 18, 2022, each of Ben Friedman and David Zolty resigned his position as a director of the company.공시 • May 13Cell Source, Inc. announced delayed 10-Q filingOn 05/12/2022, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 01Cell Source, Inc. announced delayed annual 10-K filingOn 03/31/2022, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Mar 21USPTO Issues New Patents for Cell Source's Veto Cell TechnologyCell Source, Inc. announced that it has received USPTO issuance notices for two patents covering its Veto Cell technology. The first patent, "Veto Cells Generated from Memory T Cells", describes Veto Cells that safely elicit patient acceptance of transplanted cells, such as stem cells, by overcoming the barriers of graft rejection and graft versus host disease (GvHD). Veto Cells are also capable of fighting potential viral and bacterial infections and can treat unresponsive cancers or cancers where limited treatment options exist. The second patent, "Methods of Transplantation and Disease Treatment", describes an invention in which Veto Cells act as unique, powerful companion cells that allow cellular therapies such as CAR-T and NK to be safely tolerated by the patient without transplant rejection or graft vs. host disease (GvHD) – while increasing overall combined treatment impact. The patents describe Veto Cell inventions in which Veto Cells work in conjunction with existing stem cell transplant therapies to protect the patient from transplant-related complications while increasing overall treatment efficacy, as well as inventions in which Veto Cells have been exposed to third-party antigens, thereby enabling Veto Cells to work on their own to effectively target cancers that have not responded to genetically modified T-cell therapies or where these therapies do not currently exist.공시 • Mar 14Cell Source, Inc. Announces its Veto T-Cell Bone Marrow Transplant Safely Demonstrates Potential Cure for Sickle Cell Anemia in Preclinical TrialsCell Source, Inc. announced that its fully mismatched mouse Veto Cell based BMT protocol has overcome significant challenges to durably prevent the onset of the pathological parameters of sickle cell disease (SCD) including complete conversion to normal, donor-derived red blood cells. The study, correction of murine sickle cell disease by allogeneic hæmatopoietic cell transplantation with anti-3rd party veto cells, published online by BMT Journalon March 3, 2021. As noted in BMT Journal, the Veto Cell protocol was able to safely and efficaciously achieve durable, donor-derived chimerism in mice prone to sickle cell disease (i.e., the donor's transplanted healthy cells begin to be produced by the recipient mice instead of the host defective cells) and prevent onset of SCD pathology by overcoming several significant challenges, including: the need for safer partially or fully mismatched bone marrow transplantation (BMT) protocols; the challenge of transplant rejection under reduced intensity conditioning (RIC); and the possibility of graft vs. host disease under RIC. A phase 1/2 clinical trial is currently in progress testing the safety and efficacy of the company’s Veto Cells in patients with hematological cancers or with non-malignant hematological diseases including SCD.공시 • Feb 26Cell Source, Inc. Appoints Joseph Rosenthal to Scientific Advisory BoardCell Source, Inc. announced that Joseph Rosenthal has joined its Scientific Advisory Board. Dr. Rosenthal is currently the Director of Pediatric Hematology-Oncology and Barron Hilton Professor & Chair in Pediatrics at City of Hope National Medical Center in Duarte, CA.매출 및 비용 세부 내역Cell Source가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:CLCS 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 250-62231 Dec 240-62230 Sep 240-72230 Jun 240-62231 Mar 240-62231 Dec 230-73230 Sep 230-73230 Jun 230-73231 Mar 230-73231 Dec 220-62230 Sep 220-62230 Jun 220-62231 Mar 220-62231 Dec 210-63130 Sep 210-73130 Jun 210-63131 Mar 210-63131 Dec 200-53130 Sep 200-52130 Jun 200-52231 Mar 200-51231 Dec 190-51330 Sep 190-51330 Jun 190-41131 Mar 190-31131 Dec 180-31130 Sep 180-31130 Jun 180-31131 Mar 180-31131 Dec 170-31130 Sep 170-11130 Jun 170-11131 Mar 170-11131 Dec 160-11130 Sep 160-31130 Jun 160-31131 Mar 160-31131 Dec 150-31130 Sep 150-321양질의 수익: CLCS 은(는) 현재 수익성이 없습니다.이익 마진 증가: CLCS는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 CLCS의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: 현재 수익성이 없어 지난 1년간 CLCS의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: CLCS은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(54.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: CLCS의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/08 08:55종가2026/06/08 00:00수익2025/03/31연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cell Source, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Mar 29Cell Source, Inc. announced delayed annual 10-K filingOn 03/28/2025, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Nov 21Cell Source, Inc. Shared Positive Interim Results from Its Phase 1/2 First-In-Human Clinical Trial Conducted At the University of Texas Md Anderson Cancer CenterCell Source, Inc. shared positive interim results from its Phase 1/2 First-in-Human clinical trial conducted at The University of Texas MD Anderson Cancer Center. The trial has treated 15 patients using Cell Source's proprietary Veto Cell technology in stem cell transplants for malignant and non-malignant hematologic diseases. These early results indicate both safety and efficacy, marking a promising advance in stem cell transplant outcomes. Breakthrough Results for Safer and Effective Transplants Previously presented at the American Society for Hematology (ASH) Annual Meeting, the interim study results highlight: Consistent engraftment without severe GvHD: Achieved at 42 days post- transplant with T-cell-depleted, haploidentical stem cell transplants under reduced intensity conditioning (RIC).No toxicity linked to Veto Cells: No patients experienced adverse effects directly associated with Veto Cells. Enhanced protocol: A mild conditioning regimen, combined with Rituximab to prevent antibody-related complications, makes transplants safer and suitable for a broader range of patients. These findings underscore the potential of Veto Cells to increase access to life-saving allogeneic transplants for cancer patients and individuals with non-malignant blood disorders, supporting the strategic advancement of Cell Source's technology. Comparable Successes Demonstrate Market Potential The cell therapy and immunotherapy market has seen robust investor interest, with several start-up companies achieving multibillion-dollar valuations after clinical success. For example, Kite Pharma and Juno Therapeutics were acquired for $12 billion and $9 billion, respectively, following successful clinical outcomes and regulatory approvals in similar areas of cellular therapy. These precedents highlight the significant financial upside for novel treatments that achieve distinctive clinical efficacy and regulatory milestones. With Cell Source's Veto Cell platform showing early promise in achieving safer and thus more effective stem cell transplants without severe GvHD, the Company is strategically positioned to capitalize on this expanding market. The total addressable market (TAM) for hematological therapeutics, including both cancer and nonmalignant diseases, is estimated to be in excess of $100 billion, underscoring the vast commercial potential for Veto Cells to gain market traction as the platform advances through clinical trials. Pathway to Market and Competitive EdgeCell Source's Veto Cell technology offers a unique advantage by combining reduced immune suppression with avoidance to GvHD, making it an attractive alternative to current stem cell transplant methods. The Company's Veto Cell platform is also being developed for organ transplant applications, potentially allowing for partially mismatched donors as well as reducing or possibly even eliminating reliance on lifelong immunosuppression post-transplant.
공시 • Aug 15Cell Source, Inc. announced delayed 10-Q filingOn 08/14/2024, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 02Cell Source, Inc. announced delayed annual 10-K filingOn 04/01/2024, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Aug 17Cell Source, Inc. announced delayed 10-Q filingOn 08/15/2023, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
New Risk • Jun 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$2.9m free cash flow). Shares are highly illiquid. Negative equity (-US$12m). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$14.9k market cap). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Shareholders have been diluted in the past year (8.0% increase in shares outstanding).
공시 • May 17Cell Source, Inc. announced delayed 10-Q filingOn 05/16/2023, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Jul 22Cell Source, Inc. Announces Board ResignationsCell Source, Inc. announced that onJuly 18, 2022, each of Ben Friedman and David Zolty resigned his position as a director of the company.
공시 • May 13Cell Source, Inc. announced delayed 10-Q filingOn 05/12/2022, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 01Cell Source, Inc. announced delayed annual 10-K filingOn 03/31/2022, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Mar 21USPTO Issues New Patents for Cell Source's Veto Cell TechnologyCell Source, Inc. announced that it has received USPTO issuance notices for two patents covering its Veto Cell technology. The first patent, "Veto Cells Generated from Memory T Cells", describes Veto Cells that safely elicit patient acceptance of transplanted cells, such as stem cells, by overcoming the barriers of graft rejection and graft versus host disease (GvHD). Veto Cells are also capable of fighting potential viral and bacterial infections and can treat unresponsive cancers or cancers where limited treatment options exist. The second patent, "Methods of Transplantation and Disease Treatment", describes an invention in which Veto Cells act as unique, powerful companion cells that allow cellular therapies such as CAR-T and NK to be safely tolerated by the patient without transplant rejection or graft vs. host disease (GvHD) – while increasing overall combined treatment impact. The patents describe Veto Cell inventions in which Veto Cells work in conjunction with existing stem cell transplant therapies to protect the patient from transplant-related complications while increasing overall treatment efficacy, as well as inventions in which Veto Cells have been exposed to third-party antigens, thereby enabling Veto Cells to work on their own to effectively target cancers that have not responded to genetically modified T-cell therapies or where these therapies do not currently exist.
공시 • Mar 14Cell Source, Inc. Announces its Veto T-Cell Bone Marrow Transplant Safely Demonstrates Potential Cure for Sickle Cell Anemia in Preclinical TrialsCell Source, Inc. announced that its fully mismatched mouse Veto Cell based BMT protocol has overcome significant challenges to durably prevent the onset of the pathological parameters of sickle cell disease (SCD) including complete conversion to normal, donor-derived red blood cells. The study, correction of murine sickle cell disease by allogeneic hæmatopoietic cell transplantation with anti-3rd party veto cells, published online by BMT Journalon March 3, 2021. As noted in BMT Journal, the Veto Cell protocol was able to safely and efficaciously achieve durable, donor-derived chimerism in mice prone to sickle cell disease (i.e., the donor's transplanted healthy cells begin to be produced by the recipient mice instead of the host defective cells) and prevent onset of SCD pathology by overcoming several significant challenges, including: the need for safer partially or fully mismatched bone marrow transplantation (BMT) protocols; the challenge of transplant rejection under reduced intensity conditioning (RIC); and the possibility of graft vs. host disease under RIC. A phase 1/2 clinical trial is currently in progress testing the safety and efficacy of the company’s Veto Cells in patients with hematological cancers or with non-malignant hematological diseases including SCD.
공시 • Feb 26Cell Source, Inc. Appoints Joseph Rosenthal to Scientific Advisory BoardCell Source, Inc. announced that Joseph Rosenthal has joined its Scientific Advisory Board. Dr. Rosenthal is currently the Director of Pediatric Hematology-Oncology and Barron Hilton Professor & Chair in Pediatrics at City of Hope National Medical Center in Duarte, CA.